Mild Cognitive Impairment
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The researchers first conducted a preliminary assessment of the participants according to the Jak/Bondi criteria to determine whether they met the diagnostic criteria for mild cognitive impairment (MCI). This assessment included tests across three cognitive domains: memory, language, and attention/executive function. Participants who scored abnormally low on these tests were classified as having MCI. The diagnostic criteria were explicitly defined as follows: scores on at least two neuropsychological measures within the same cognitive domain falling more than one standard deviation below the age- and education-adjusted normative mean, or abnormal performance observed across all three cognitive domains. Participants diagnosed with MCI were further subdivided into subgroups: those with impaired memory function were classified as amnestic MCI (aMCI), while those with impaired language ability, impaired attention/executive function (or a combination of both but without memory impairment) were classified as non-amnesic MCI (naMCI). The remaining participants who did not meet the MCI criteria were further classified as healthy controls (HC). These participants were assessed for everyday memory problems using the Subjective Cognitive Decline-Questionnaire 9 (SCD-Q9), which includes items such as "forgetting where objects are placed" or "forgetting important dates." One point was assigned for each memory-related complaint endorsed, resulting in a total SCD-Q9 score ranging from 0 to 9. Participants with a score below 5 were classified as HC, while those with a score of 5 or higher were classified as having subjective cognitive decline (SCD).
Exclusion criteria
Exclusion criteria: 1. Met the diagnostic criteria for dementia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2. Had a history of severe diseases known to affect central nervous system function, such as Parkinson's disease, epilepsy, stroke (with confirmed neurological deficits), brain tumors, or a history of moderate to severe traumatic brain injury. 3. Had a history of severe psychiatric disorders, such as major depression (Hamilton Depression Rating Scale score >24), schizophrenia, or bipolar disorder. 4. Presented with severe aphasia, apraxia, agnosia, or visual field defects that precluded understanding instructions or cooperating with the eye-tracking test. 5. Had severe failure of major visceral organs (e.g., heart, liver, kidneys). 6. Had a history of current or previous alcohol or substance abuse. 7. Were currently taking or had a history of taking medications that may significantly affect central nervous system function (e.g., benzodiazepines, antipsychotics, cholinesterase inhibitors). 8. Had scalp lesions, infections, or intracranial metal implants that contraindicated the use of the functional near-infrared spectroscopy (fNIRS) probe cap.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemodynamic Levels of HbO in Bilateral Prefrontal Cortex Regions of Interest; | — |
Secondary
| Measure | Time frame |
|---|---|
| AST error rate;Error correction rate;Cortical thickness;AST latency;Completion time of TMT-A/B test; | — |
Countries
China
Contacts
Public ContactNi Guoxin
The First Affiliated Hospital of Xiamen University
Outcome results
None listed